Evidence map›Paper›PMID 29105026›Full record

ReviewVirchows Archiv : an international journal of pathology2018

Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review.

Rola H Ali, Catalin Taraboanta, Tareq Mohammad, Malcolm M Hayes, Diana N Ionescu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Rola H AliPathology Department, Health Sciences Center, Kuwait University, Kuwait, Kuwait.
Catalin TaraboantaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-9574-623X
Tareq MohammadDepartment of Pathology, University of California, Los Angeles, CA, USA.
Malcolm M HayesDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Diana N IonescuDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. dionescu@bccancer.bc.ca.
BC Cancer Agency · CAKuwait University · KWUniversity of British Columbia · CAUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic tumors to the breast are rare but constitute a major diagnostic dilemma. Of these, non-mammary carcinomatous metastases to the breast are particularly challenging and, without a clinical history, may be extremely difficult to distinguish from primary breast carcinoma (PBC). We specifically studied metastatic tumors of pulmonary origin, as the lung is one of the major primary sites for carcinomatous metastasis to breast. Sixteen metastatic lung tumors to the breast were identified in our archives between 1996 and 2017 including 12 non-small cell lung carcinomas (NSCLC), one large-cell neuroendocrine, one atypical carcinoid, and two small-cell carcinomas. Adenocarcinoma was the most frequent amongst the NSCLCs (11/14). We retrieved the clinical information of these cases and reviewed the pathological characteristics to provide practical tools for pathologists to aid in their identification. Even in the absence of a clinical history of lung cancer, metastatic pulmonary adenocarcinoma to the breast should be considered in at least one of the following scenarios: (1) single or multiple well-circumscribed lesions of the breast that lack an in situ component and that are accompanied by distant metastases but negative axillary lymph nodes, (2) breast tumors that are triple negative yet not high-grade, or (3) breast tumors presenting as stage 4 disease and/or having an unusually aggressive clinical course on standard breast therapy. Accurate and timely diagnosis of these tumors is mandatory because of treatment and prognostic implications.

Indexed as

AgedBreast NeoplasmsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedBreastLungMetastatic carcinomaNon-small cell

Identifiers

PMID29105026
OpenAlexW2766345712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.